PDF herunterladen
Aktuelle Rheumatologie 2022; 47(04): 303-314
DOI: 10.1055/a-1876-2616
Übersichtsarbeit

Differentialdiagnose Vaskulitis und Vaskulopathie aus dermatologischer Sicht

Differential Diagnosis of Vasculitis and Vasculopathy from a Dermatological Point of View
Carolin Mitschang
1   Abteilung für Wundheilung/Phlebologie, Universitätsklinikum Münster Klinik für Hautkrankheiten, Münster, Germany
,
Jan Ehrchen
2   Abteilung für Autoimmun-Dermatologie, Universitätsklinikum Münster Klinik für Hautkrankheiten, Münster, Germany
,
Tobias Görge
1   Abteilung für Wundheilung/Phlebologie, Universitätsklinikum Münster Klinik für Hautkrankheiten, Münster, Germany
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Zusammenfassung

Vaskulopathien und Vaskulitiden stellen diagnostisch und therapeutisch eine interdisziplinäre Herausforderung dar. Zugrunde liegen unterschiedliche pathophysiologische Mechanismen, die zu vielfältigen klinischen Krankheitsbildern führen können und therapeutisch unterschiedliche Ansätze erlauben. Sowohl Vaskulitiden als auch Vaskulopathien müssen nicht zwangsläufig mit einer Systembeteiligung einhergehen, sondern können auch als rein kutane Varianten auftreten. Aufgrund mangelnder pathognomonischer Laborparameter ist die Diagnose häufig klinisch zu stellen. Dieser Artikel soll den differentialdiagnostischen Blick, insbesondere auf die kutanen Manifestationsformen bei Vaskulopathien und Vaskulitiden, schärfen.

Abstract

Vasculopathies and vasculitides pose an interdisciplinary challenge in terms of diagnosis and therapy. They are based on different pathophysiological mechanisms that can lead to clinical symptoms and allow different therapeutic approaches. Neither vasculitides nor vasculopathies have necessarily to be associated with systemic involvement, but can also occur as purely cutaneous variants. Due to the lack of pathognomonic laboratory parameters, the diagnosis is often clinical. This article is intended to focus on the differential diagnostic view, particularly in the case of cutaneous manifestations of vasculitis and vasculopathies.

Schlüsselwörter

Vaskulitis - Vaskulopathie - Livedovaskulopathie - Differentialdiagnose

Key words

Vasculitis - vasculopathy - livedoid vasculopathy - differential diagnosis


Publikationsverlauf

Artikel online veröffentlicht:
11. August 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Jennette JC, Falk RJ, Bacon PA. et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11
    CrossrefPubMedSuche in Google Scholar
  • 2 Mitschang C, Görge T. Diagnosis and treatment of vasculitic ulcerations. Hautarzt 2020; 71: 870-879
    CrossrefPubMedSuche in Google Scholar
  • 3 Sunderkötter CH, Zelger B, Chen K-R. et al. Nomenclature of Cutaneous Vasculitis: Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol 2018; 70: 171-184
    CrossrefPubMedSuche in Google Scholar
  • 4 Sunderkötter C, Roth J, Bonsmann G. Leukocytoclastic vasculitis. Hautarzt 2004; 55: 759-783 quiz 784-5
    CrossrefPubMedSuche in Google Scholar
  • 5 Díaz-Pérez JL, De Lagrán ZM, Díaz-Ramón JL. et al. Cutaneous polyarteritis nodosa. Semin Cutan Med Surg 2007; 26: 77-86
    CrossrefPubMedSuche in Google Scholar
  • 6 Tsianakas A, Ehrchen JM, Presser D. et al. Scalp necrosis in giant cell arteritis: case report and review of the relevance of this cutaneous sign of large-vessel vasculitis. J Am Acad Dermatol 2009; 61: 701-706
    CrossrefPubMedSuche in Google Scholar
  • 7 Gonzalez CD, Florell SR, Bowen AR. et al. Histopathologic vasculitis from the periulcer edge: A retrospective cohort study. J Am Acad Dermatol 2019; 81: 1353-1357
    CrossrefPubMedSuche in Google Scholar
  • 8 Pillebout E, Sunderkötter C. IgA vasculitis. Semin Immunopathol 2021; 43: 729-738
    CrossrefPubMedSuche in Google Scholar
  • 9 Schirmer JH, Aries PM, de Groot K. et al. S1 guidelines Diagnostics and treatment of ANCA-associated vasculitis. Z Rheumatol 2017; 76: 77-104
    CrossrefPubMedSuche in Google Scholar
  • 10 Aries PM, Hellmich B, Gross WL. Diagnosis und therapy of ANCA-associated vasculitis. Dtsch Med Wochenschr 2006; 131: 443-446
    Thieme ConnectPubMedSuche in Google Scholar
  • 11 Sunderkötter C. Vaskulitis und Vaskulopathien. In: Plewig G, Ruzicka T, Kaufmann R, Hertl M, Hrsg. Braun-Falco’s Dermatologie, Venerologie und Allergologie. Berlin, Heidelberg: Springer Berlin Heidelberg; 2018: 1139-1182
    CrossrefSuche in Google Scholar
  • 12 Marzano AV, Raimondo MG, Berti E. et al. Cutaneous Manifestations of ANCA-Associated Small Vessels Vasculitis. Clin Rev Allergy Immunol 2017; 53: 428-438
    CrossrefPubMedSuche in Google Scholar
  • 13 Berden AE, Ferrario F, Hagen EC. et al. Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol 2010; 21: 1628-1636
    CrossrefPubMedSuche in Google Scholar
  • 14 Aasarød K, Bostad L, Hammerstrøm J. et al. Renal histopathology and clinical course in 94 patients with Wegener’s granulomatosis. Nephrol Dial Transplant 2001; 16: 953-960
    CrossrefPubMedSuche in Google Scholar
  • 15 Hauer HA, Bajema IM, van Houwelingen HC. et al. Determinants of outcome in ANCA-associated glomerulonephritis: a prospective clinico-histopathological analysis of 96 patients. Kidney Int 2002; 62: 1732-1742
    CrossrefPubMedSuche in Google Scholar
  • 16 Kluger N, Pagnoux C, Guillevin L. et al. Comparison of cutaneous manifestations in systemic polyarteritis nodosa and microscopic polyangiitis. Br J Dermatol 2008; 159: 615-620
    CrossrefPubMedSuche in Google Scholar
  • 17 Ratzinger G, Zelger BG, Carlson JA. et al. Vasculitic wheel – an algorithmic approach to cutaneous vasculitides. J Dtsch Dermatol Ges 2015; 13: 1092-1117
    CrossrefPubMedSuche in Google Scholar
  • 18 Munera-Campos M, Bielsa I, Martínez-Morillo M. et al. Manifestations, clinical course and prognostic markers in cutaneous polyarteritis nodosa. J Dtsch Dermatol Ges 2020; 18: 1250-1259
    CrossrefPubMedSuche in Google Scholar
  • 19 de Boysson H, Guillevin L. Polyarteritis Nodosa Neurologic Manifestations. Neurol Clin 2019; 37: 345-357
    CrossrefPubMedSuche in Google Scholar
  • 20 Morgan AJ, Schwartz RA. Cutaneous polyarteritis nodosa: a comprehensive review. Int J Dermatol 2010; 49: 750-756
    CrossrefPubMedSuche in Google Scholar
  • 21 Ricotti C, Kowalczyk JP, Ghersi M. et al. The diagnostic yield of histopathologic sampling techniques in PAN-associated cutaneous ulcers. Arch Dermatol 2007; 143: 1334-1336
    CrossrefPubMedSuche in Google Scholar
  • 22 Bauzá A, España A, Idoate M. Cutaneous polyarteritis nodosa. Br J Dermatol 2002; 146: 694-699
    CrossrefPubMedSuche in Google Scholar
  • 23 Diaz-Perez JL, Schroeter AL, Winkelmann RK. Cutaneous periarteritis nodosa: immunofluorescence studies. Arch Dermatol 1980; 116: 56-58
    CrossrefPubMedSuche in Google Scholar
  • 24 Rogalski C, Sticherling M. Panarteritis cutanea benigna--an entity limited to the skin or cutaneous presentation of a systemic necrotizing vasculitis? Report of seven cases and review of the literature. Int J Dermatol 2007; 46: 817-821
    CrossrefPubMedSuche in Google Scholar
  • 25 Daoud MS, Hutton KP, Gibson LE. Cutaneous periarteritis nodosa: a clinicopathological study of 79 cases. Br J Dermatol 1997; 136: 706-713
    CrossrefPubMedSuche in Google Scholar
  • 26 Boehm I, Bauer R. Low-dose methotrexate controls a severe form of polyarteritis nodosa. Arch Dermatol 2000; 136: 167-169
    CrossrefPubMedSuche in Google Scholar
  • 27 Lobo I, Ferreira M, Silva E. et al. Cutaneous polyarteritis nodosa treated with intravenous immunoglobulins. J Eur Acad Dermatol Venereol 2008; 22: 880-882
    CrossrefPubMedSuche in Google Scholar
  • 28 Buttgereit F, Dejaco C, Matteson EL. et al. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. JAMA 2016; 315: 2442-2458
    CrossrefPubMedSuche in Google Scholar
  • 29 Wang X, Hu ZP, Lu W. et al. Giant cell arteritis. Rheumatol Int 2008; 29: 1-7
    CrossrefPubMedSuche in Google Scholar
  • 30 Tago M, Oishi T, Makio S. et al. Tongue Necrosis: An Atypical Sign of Giant-cell Arteritis. Intern Med 2021; 60: 3347-3348
    CrossrefPubMedSuche in Google Scholar
  • 31 Chua-Aguilera CJ, Möller B, Yawalkar N. Skin Manifestations of Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Spondyloarthritides. Clin Rev Allergy Immunol 2017; 53: 371-393
    CrossrefPubMedSuche in Google Scholar
  • 32 Cojocaru M, Cohocaru IM, Chico B. New insight into the rheumatoid vasculitis. Rom J Intern Med 2015; 53: 128-132
    CrossrefPubMedSuche in Google Scholar
  • 33 McRorie ER, Ruckley CV, Nuki G. The relevance of large-vessel vascular disease and restricted ankle movement to the aetiology of leg ulceration in rheumatoid arthritis. Br J Rheumatol 1998; 37: 1295-1298
    CrossrefPubMedSuche in Google Scholar
  • 34 Lora V, Cerroni L, Cota C. Skin manifestations of rheumatoid arthritis. G Ital Dermatol Venereol 2018; 153: 243-255
    CrossrefPubMedSuche in Google Scholar
  • 35 Bywaters EG, Scott JT. The Natural History of Vascular Lesions in Rheumatoid Arthritis. J Chronic Dis 1963; 16: 905-914
    CrossrefPubMedSuche in Google Scholar
  • 36 Sayah A, English JC. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol 2005; 53: 191-209 quiz 210-2
    CrossrefPubMedSuche in Google Scholar
  • 37 Sanchez NP, Winkelmann RK, Schroeter AL. et al. The clinical and histopathologic spectrums of urticarial vasculitis: study of forty cases. J Am Acad Dermatol 1982; 7: 599-605
    CrossrefPubMedSuche in Google Scholar
  • 38 Mehregan DR, Hall MJ, Gibson LE. Urticarial vasculitis: a histopathologic and clinical review of 72 cases. J Am Acad Dermatol 1992; 26: 441-448
    CrossrefPubMedSuche in Google Scholar
  • 39 Kuhn A, Schuppe HC, Ruzicka T. et al. Rare cutaneous manifestaions of lupus erythematosus. A clinical overview. Hautarzt 2000; 51: 818-825
    CrossrefPubMedSuche in Google Scholar
  • 40 Kittridge A, Routhouska SB, Korman NJ. Dermatologic manifestations of Sjögren syndrome. J Cutan Med Surg 2011; 15: 8-14
    CrossrefPubMedSuche in Google Scholar
  • 41 Koh JH, Park Y, Lee J. et al. Hypergammaglobulinaemia predicts glandular and extra-glandular damage in primary Sjögren’s syndrome: results from the KISS cohort study. Clin Exp Rheumatol 2021; 39: 114-122
    CrossrefPubMedSuche in Google Scholar
  • 42 Lawley TJ, Moutsopoulos HM, Katz SI. et al. Demonstration of circulating immune complexes in Sjögren’s syndrome. J Immunol 1979; 123: 1382-1387
    CrossrefPubMedSuche in Google Scholar
  • 43 Sunderkötter C, Michl C. Cutaneous alterations in vasculitides: Part 2: Special aspects of diseases of large, medium and small vessels. Internist (Berl) 2019; 60: 805-813
    CrossrefPubMedSuche in Google Scholar
  • 44 Mitschang C, Görge T. Purpura pigmentosa progressiva. Phlebologie 2017; 46: 358-360
    Thieme ConnectPubMedSuche in Google Scholar
  • 45 Sherertz EF. Pigmented purpuric eruptions. Semin Thromb Hemost 1984; 10: 190-195
    Thieme ConnectPubMedSuche in Google Scholar
  • 46 Sardana K, Sarkar R, Sehgal VN. Pigmented purpuric dermatoses: an overview. Int J Dermatol 2004; 43: 482-488
    CrossrefPubMedSuche in Google Scholar
  • 47 Iwatsuki K, Aoshima T, Tagami H. et al. Immunofluorescence study in purpura pigmentosa chronica. Acta Derm Venereol 1980; 60: 341-345
    CrossrefPubMedSuche in Google Scholar
  • 48 Schober SM, Peitsch WK, Bonsmann G. et al. Early treatment with rutoside and ascorbic acid is highly effective for progressive pigmented purpuric dermatosis. J Dtsch Dermatol Ges 2014; 12: 1112-1119
    CrossrefPubMedSuche in Google Scholar
  • 49 Laufer F. The treatment of progressive pigmented purpura with ascorbic acid and a bioflavonoid rutoside. J Drugs Dermatol 2006; 5: 290-293
    PubMedSuche in Google Scholar
  • 50 Weishaupt C, Strölin A, Kahle B. et al. Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis. J Eur Acad Dermatol Venereol 2019; 33: 1784-1791
    CrossrefPubMedSuche in Google Scholar
  • 51 Schiffmann M-L, Dissemond J, Erfurt-Berge C. et al. S1-Leitlinie Diagnostik und Therapie der Livedovaskulopathie. J Dtsch Dermatol Ges 2021; 19: 1667-1678
    CrossrefPubMedSuche in Google Scholar
  • 52 Weishaupt C, Strölin A, Kahle B. et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. Lancet Haematol 2016; 3: e72-e79
    CrossrefPubMedSuche in Google Scholar
  • 53 Baker WFJR, Bick RL. The clinical spectrum of antiphospholipid syndrome. Hematol Oncol Clin North Am 2008; 22: 33-52 v-vi.
    CrossrefPubMedSuche in Google Scholar
  • 54 Gkogkolou P, Ehrchen J, Goerge T. Severe antiphospholipid antibody syndrome - response to plasmapheresis and rituximab. J Dermatolog Treat 2017; 28: 564-566
    CrossrefPubMedSuche in Google Scholar
  • 55 Francès C, Niang S, Laffitte E. et al. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis Rheum 2005; 52: 1785-1793
    CrossrefPubMedSuche in Google Scholar
  • 56 Crome CR, Rajagopalan S, Kuhan G. et al. Antiphospholipid syndrome presenting with acute digital ischaemia, avascular necrosis of the femoral head and superior mesenteric artery thrombus. BMJ Case Rep 2012; 2012
    CrossrefPubMedSuche in Google Scholar
  • 57 Cervera R, Tektonidou MG, Espinosa G. et al. Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (II): thrombocytopenia and skin manifestations. Lupus 2011; 20: 174-181
    CrossrefPubMedSuche in Google Scholar